SynthesisBMC anesthesiology2025
Nebulized dexmedetomidine for post-dural puncture headache after cesarean delivery: a systematic review and meta-analysis.
Synthesis in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThere are limited effective non-invasive treatment options for post-dural puncture headache (PDPH) following cesarean delivery. This meta-analysis aimed to investigate the efficacy and safety of nebulized dexmedetomidine in treating PDPH after cesarean delivery.
methodsElectronic databases were systematically searched from the inception to March 2025. Primary outcomes included pain scores based on the numerical rating scale (NRS) and the visual analogue scale (VAS) at 6, 12, 24, 48, and 72 h after the intervention. Secondary outcomes included the need for epidural blood patch (EBP) and adverse events, such as bradycardia and dry mouth. The Cochrane Risk of Bias 2 (RoB 2) tool was employed to assess the quality of the included studies, and the certainty of evidence was evaluated using the grading of recommendations assessment, development, and evaluation (GRADE) approach.
resultsFour randomized controlled trials with 228 patients were included in this meta-analysis. Compared to participants in the control group who received saline or fentanyl, patients with PDPH who received nebulized dexmedetomidine following cesarean delivery exhibited lower pain scores at 6, 12, 24, 48, and 72 hours after the intervention. The quality of evidence ranged from 'very low' to 'moderate'. The nebulized dexmedetomidine group less frequently needed EBP compared to the control group, while there were no significant differences between the two groups in terms of adverse effects.
conclusionNebulized dexmedetomidine is a promising non-invasive option for managing PDPH in patients undergoing cesarean delivery. It effectively reduces pain intensity and decreases the need for invasive procedures, such as epidural blood patches, with an acceptable safety profile. This nebulized delivery method may offer practical advantages over traditional systemic approaches, particularly in the postpartum setting.
trial registrationWe registered this network meta-analysis with PROSPERO (registration no. CRD420251016279).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.